Engineering nanoallergens to investigate origins of immunogenicity and cross-reactivity in cephalosporin allergy
Journal of Allergy and Clinical Immunology · 2025-06 · 155 (6) · 1957-1967.e1
DOI: 10.1016/j.jaci.2025.02.022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025-06. Verfasst von Emily K Bromley und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biomolecular Engineering, University of Notre Dame, Notre Dame, Ind; Berthiaume Institute for Precision Health, University…. Hauptthemen laut MEDLINE: Drug Hypersensitivity, Allergens, Haptens, Cephalosporins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
BACKGROUND: A major obstacle to the effective diagnosis of cephalosporin allergies is that the haptens, or segments of their molecular structures, which are responsible for the initiation of an immunogenic response, are unknown. OBJECTIVE: This study aimed to identify immunogenic moieties of cefazolin to accurately predict IgE-mediated allergy and cross-reactivity with other cephalosporin antibiotics. METHODS: Hapten immunogenicity analysis is performed using liposomal nanoallergens integrated in a cellular degranulation assay to quantify secreted allergic mediators. RBL-SX38 cells were primed with purified human monoclonal IgE or patient plasma samples before nanoallergen challenge. The monoclonal IgE priming consisted of dust mite- or peanut-specific negative controls and were compared against a cefazolin-specific monoclonal IgE. The plasma samples, in contrast, came from 3 drug allergy-negative control patients, or 2 cefazolin-allergic patients who provided 3 samples. RESULTS: Multiple forms of cefazolin are immunogenic when multivalently presented by nanoallergens, and there may be alternate nanoparticle formulations that can effectively diagnose IgE-mediated cefazolin allergy in patients. Additionally, common R1 or R2 groups in cephalosporin molecular structures do not singularly identify shared cross-reactivity. CONCLUSION: This study highlights an innovative method to reproducibly distinguish cefazolin-allergic from nonallergic patients using finely tuned cefazolin-hapten-presenting nanoallergens in conjunction with an in vitro cellular degranulation assay.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical and Biomolecular Engineering, University of Notre Dame, Notre Dame, Ind; Berthiaume Institute for Precision Health, University of Notre Dame, Notre Dame, Ind; Mike and Josie Harper Cancer Research…
- Berthiaume Institute for Precision Health, University of Notre Dame, Notre Dame, Ind; Mike and Josie Harper Cancer Research Institute, University of Notre Dame, Notre Dame, Ind; Department of Chemistry and Biochemistry,…
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn.
- Department of Internal Medicine, Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, Tex.
- Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn.
- Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Mass.
Förderung
- NIAID NIH HHS
- National Institutes of Health
Zitieren
APA
Bromley, E. K., Sjoerdsma, J. N., Horgan, C. L., Smith, S. A., Khan, D. A., Phillips, E. J., Blumenthal, K. G., Stone, C. A., & Bilgicer, B. (2025). Engineering nanoallergens to investigate origins of immunogenicity and cross-reactivity in cephalosporin allergy. Journal of Allergy and Clinical Immunology, 155(6), 1957-1967.e1. https://doi.org/10.1016/j.jaci.2025.02.022
Vancouver
Bromley EK, Sjoerdsma JN, Horgan CL, Smith SA, Khan DA, Phillips EJ, et al. Engineering nanoallergens to investigate origins of immunogenicity and cross-reactivity in cephalosporin allergy. Journal of Allergy and Clinical Immunology. 2025;155(6):1957-1967.e1. doi:10.1016/j.jaci.2025.02.022
BibTeX
@article{Bromley2025,
author = {Bromley, Emily K and Sjoerdsma, Jenna N and Horgan, Caitlin L and Smith, Scott A and Khan, David A and Phillips, Elizabeth J and Blumenthal, Kimberly G and Stone, Cosby A and Bilgicer, Basar},
title = {Engineering nanoallergens to investigate origins of immunogenicity and cross-reactivity in cephalosporin allergy},
journal = {Journal of Allergy and Clinical Immunology},
year = {2025},
volume = {155},
number = {6},
pages = {1957--1967.e1},
doi = {10.1016/j.jaci.2025.02.022}
}
EUVIMED